Xeris Biopharma Holdings (XERS) Return on Equity (2021 - 2025)
Historic Return on Equity for Xeris Biopharma Holdings (XERS) over the last 5 years, with Q3 2025 value amounting to 1.55%.
- Xeris Biopharma Holdings' Return on Equity fell 11000.0% to 1.55% in Q3 2025 from the same period last year, while for Sep 2025 it was 1.55%, marking a year-over-year decrease of 11000.0%. This contributed to the annual value of 3.01% for FY2024, which is 62600.0% up from last year.
- Xeris Biopharma Holdings' Return on Equity amounted to 1.55% in Q3 2025, which was down 11000.0% from 1.18% recorded in Q2 2025.
- Xeris Biopharma Holdings' 5-year Return on Equity high stood at 42.68% for Q4 2023, and its period low was 7.06% during Q3 2023.
- In the last 5 years, Xeris Biopharma Holdings' Return on Equity had a median value of 0.13% in 2022 and averaged 2.6%.
- Its Return on Equity has fluctuated over the past 5 years, first skyrocketed by 445700bps in 2023, then crashed by -407900bps in 2024.
- Xeris Biopharma Holdings' Return on Equity (Quarter) stood at 2.65% in 2021, then increased by 29bps to 1.89% in 2022, then surged by 2360bps to 42.68% in 2023, then crashed by -96bps to 1.89% in 2024, then decreased by -18bps to 1.55% in 2025.
- Its Return on Equity stands at 1.55% for Q3 2025, versus 1.18% for Q2 2025 and 1.39% for Q1 2025.